Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TriLipix Exceeding Abbott’s Expectations Shortly After Launch, Execs Say

Executive Summary

Shortly after the launch of TriLipix, Abbott is seeing patients switch from its established fenofibrate TriCor to the next-generation drug- a welcoming sign for the firm, given that TriCor is expected to face generics in 2011

You may also be interested in...

With Strong Humira Sales Growth, Abbott Is Bullish On Its Second-Quarter Results

The drug maker also reports rising sales for its dyslipidemia franchise.

AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix

AstraZeneca and Abbott announce co-promotion agreement for TriLipix ahead of an FDA decision on a jointly-developed investigational Crestor/TriLipix compound.

American College Of Cardiology Meeting, In Brief

Statin "reloading" may help angioplasty patients avoid heart attack: The pleiotropic effects of statins extend to the PCI lab, where they show benefits for patients dosed before angioplasty, according to evidence presented during the American College of Cardiology scientific sessions in Orlando, Fla., March 29-31. In the ARMYDA-RECAPTURE trial, patients with stable angina or non-ST-elevation acute coronary syndrome chronically treated with statins were "reloaded" with 80 mg of atorvastatin (Pfizer's Lipitor) 12 hours before percutaneous coronary intervention and given another 40 mg before the procedure. They had a significant 48 percent reduction in relative risk of a major adverse cardiac event 30 days after angioplasty. The large majority of patients undergoing PCI already take statins, but the beneficial effect may wane, said principal investigator Germano Di Sciascio. A new loading dose of atorvastatin "recaptures" that effect

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts